Skip to main content
. 2023 Aug 31;13(9):1335. doi: 10.3390/biom13091335

Figure 4.

Figure 4

Cisplatin mediated the release of reduced and oxidized HMGB1 from lung cancer cells. (A) absolute quantification of reduced HMGB1 released by A549 cells (n = 3) determined by nano liquid chromatography parallel reaction monitoring/high-resolution mass spectrometry (nanoLC-PRM/HRMS) analysis. An unpaired Student’s t-test was used to compare cisplatin with PBS. (B) Site-specific cysteine (Cys) oxidation percentages calculated from nanoLC-PRM/HRMS analysis of carbamidomethyl (CAM)- and N-ethyl maleimide (NEM)-modified peptides in HMGB1 secreted from A549 cells (n = 3). (a) Cys-23. (b) Cys-45 (c) Cys-106. An unpaired Student’s t-test was used to compare cisplatin with DMSO. Error bars show ± SD.